X

Trial Profile

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 03 Aug 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary) ; Everolimus (Primary) ; Pomalidomide (Primary)
Indications Multiple myeloma
Focus Adverse reactions

Most Recent Events

30 Jul 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
03 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
14 Jul 2014 Planned End Date changed from 1 Aug 2018 to 1 Dec 2017 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com